Disruptive Behavior Disorder Treatment Market - Forecasts from 2024 to 2029

The disruptive behavior disorder treatment market is estimated to grow at a CAGR of 5.82% during the forecast period.

Disruptive behaviour disorders are a group of disorders with symptoms like frequent temper, rudeness, speaking harshly, and aggressive behavior which can impair social, familial, and personal functioning. These include conduct disorder, defiant disorder, and intermittent explosive disorder. To treat this condition there are various therapies available including family therapy, group therapy, and training which are given to patients to improve their social and emotional skills.

Driving factors for the disruptive behavior disorder treatment market

The major factor influencing the growth of the disruptive behavior disorder treatment market is the advancement in disruptive behavior disorder treatment in addition to raising awareness related to early diagnosis of mental health issues. The high potential in emerging markets with the improvement in healthcare infrastructure, and increase in unmet medical needs is also driving the disruptive behavior disorder treatment industry. Moreover, the healthcare industry in emerging countries is developing owing to the growing investment by the government of various nations, the increase in demand for enhanced healthcare services, and the rising medical tourism.

Growing prevalence of oppositional defiant disorder

Oppositional defiant disorder is a condition that affects children, and they behave in an aggressive, uncooperative, and defiant manner with others. The increasing prevalence of the oppositional defiant disorder, faster response and turnaround time, better diagnosis, non-invasive treatment procedures, availability of computational support, and reliance on the substantial number of diagnostic products are fueling the disruptive behavior disorder treatment market growth. According to the American Academy of Child & Adolescent Psychiatry, oppositional defiant disorder affects 1% to 16% of adolescents and school-aged children. Males are more likely to have the condition diagnosed than females.

Rising need to address children’s mental health

The growing involvement of various NGOs and rising awareness of disruptive behaviour disorder treatment are fueling the disruptive behavior disorder treatment market growth. For instance, a research program named Strongest Families Finland Canada (SFFC) Smart Website was launched to train parents about disruptive behaviour disorder among children to prevent Oppositional Defiant Disorder (ODD). Furthermore, the integration of disruptive disorder treatment for children with Artificial Intelligence (AI) is creating more growth opportunities. This will help children cope with stressful situations with continuous guidance from concerned doctors.

Medication management is gaining popularity

Medication management is used for treating oppositional defiant and conduct disorders. In these conditions, various synthetic and herbal drugs are prescribed for proper brain and nervous stimulation. These medications are considered in the later stages as therapies are more beneficial in the primary stage, such as group sessions, parenting modifications, and emotional skills training. These factors are influencing the growth of therapies during the forecast period which contributes to disruptive behavior disorder treatment market growth. Furthermore, there are multiple cases where the patient is unaware of the symptoms and there are delays in treatment which leads to the use of medication management.

Increasing popularity of client-focused treatments

Client-focused therapies alter the outward manifestations of a disruptive behavior disorder by focusing on the patient with the disease. The intention is to encourage the person to act in more suitable ways. In client-focused therapies, the patient interacts with a therapist one-on-one or in a group setting to acquire the necessary skills. Relaxation techniques and anger management techniques are only a couple of the coping mechanisms that may be taught in client-centred therapies.

In North America, it is projected that the disruptive behavior disorder treatment market will grow steadily.

The disruptive behaviour disorder treatment industry is anticipated to grow in North America during the projected period due to the increasing prevalence of behavioural disorders among children and adults. As people become more aware of the symptoms the disruptive behavior disorder treatment market is anticipated to grow in the region. For instance, learning sessions for parents to impart knowledge of early symptoms of disruptive behavior disorder are being conducted by the Highland Ridge Hospital of Utah. Such initiatives are predicted to contribute to the growth of the market in the region. Additionally, Asia Pacific is considered to be the second largest growing disruptive behavior disorder treatment industry owing to the increasing target population and growing substance abuse among adults.

Disruptive behavior disorder treatment programs

• Parent Programs, this program encourages parents to respond in a good manner when their youngster requests assistance or attention. Set attainable objectives for the child and better keep an eye on the child's actions.
• Child Programs, program help children feel more optimistic about their family and themselves enhancing their interpersonal, communicative, and analytical abilities to better manage anger and emotional communication
• Teen Programs, this program influences parents to spend extra time with their teens. Clearly define the rules and the penalties for breaching them.
• Teacher Programs, this program trains teachers to control student behavior in the classroom. Boost the emotional and social intelligence of kids and keep the parents involved by working with them.

Disruptive behavior disorder treatment medicines

• Stimulants, For the treatment of ADHD, the FDA has authorised stimulants. They are also used by certain medical practitioners to treat DBDs.
• Nonstimulant ADHD medicines, The FDA has authorised the use of guanfacine ER (Intuniv®) and atomoxetine (Strattera®) to treat ADHD.
• Anticonvulsant medicine, The FDA has given the anticonvulsant drug divalproex (Depakene®, Depakote®, and Depakote ER®) approval to treat seizures.
• Antipsychotics, The FDA has given the drug antipsychotics approval to treat psychosis, a kind of mental disease.

Market Key Developments

• In October 2022, The Anna Freud Centre's thorough analysis of worldwide research demonstrated the beneficial effects of treatments on young children and their careers.
• In October 2022, Lupin announced the release of Paliperidone Extended-Release Tablets, a generic version of Janssen Research and Development's Invega Extended-Release Tablets.
• In January 2022, Bionomics began the mid-stage BNC210 study to treat social anxiety disorder.

Segmentation:

By Type

• Oppositional Defiant Disorder
• Conduct Disorder
• Intermittent Explosive Disorder

By Treatment

• Medication Management
• Comprehensive Evaluation
• Parenting Therapy
• Group Therapy
• Individual Therapy

By End-User

• Hospitals
• Clinics
• Others

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others